These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16838657)

  • 1. [Side effects of interferon therapy for chronic hepatitis C].
    Arase Y
    Nihon Rinsho; 2006 Jul; 64(7):1363-7. PubMed ID: 16838657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Complications in interferon therapy for chronic hepatitis C].
    Arase Y
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):519-22. PubMed ID: 15359854
    [No Abstract]   [Full Text] [Related]  

  • 4. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
    Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The neuropsychiatric side effects of the interferon therapy in patients with chronic hepatitis B and C].
    Lapiński TW; Prokopowicz D
    Pol Merkur Lekarski; 1999 Jul; 7(37):8-11. PubMed ID: 10522402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis.
    Hosoda S; Takimura H; Shibayama M; Kanamura H; Ikeda K; Kumada H
    Psychiatry Clin Neurosci; 2000 Oct; 54(5):565-72. PubMed ID: 11043807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Sidhu-Malik NK; Kaplan AL
    J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment for chronic hepatitis C.
    Davis GL
    Rev Gastroenterol Disord; 2001; 1(2):59-72. PubMed ID: 12120176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C in hemophilic patients.
    Husa P; Smejkal P; Husová L; Penka M
    Acta Virol; 2004; 48(1):35-8. PubMed ID: 15230473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Sho Y; Fujisaki K; Sakashita H; Yamaguchi K; Tahara K; Kubozono O; Ido A; Tsubouchi H
    J Gastroenterol; 2004 Dec; 39(12):1202-4. PubMed ID: 15622486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
    Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
    Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.